| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|
| Net loss and comprehensive loss | -35,170 | -17,711 | - |
| Non-cash lease expense | 232 | 153 | 76 |
| Accretion on investment discounts | -1,375 | -1,124 | -692 |
| Stock-based compensation | 7,986 | 5,558 | 2,864 |
| Change in fair value of warrant liabilities | -22,917 | -22,353 | - |
| Prepaid expenses and other assets | -540 | 265 | -724 |
| Accounts payable, accrued expenses and other liabilities | 2,686 | 2,120 | -2,403 |
| Operating lease liabilities | -232 | -151 | -74 |
| Net cash used in operating activities | -48,250 | -33,773 | -16,060 |
| Purchase of available-for-sale short-term investments | 91,909 | 59,254 | 31,850 |
| Proceeds from maturities of available-for-sale short-term investments | 123,164 | 78,104 | 35,742 |
| Net cash provided by (used in) investing activities | 31,255 | 18,850 | 3,892 |
| Proceeds from exercise of stock options | 115 | 115 | 115 |
| Net cash provided by financing activities | 115 | 115 | 115 |
| Net change in cash and cash equivalents | -16,880 | -14,808 | -12,053 |
| Cash and cash equivalents at beginning of period | 20,549 | - | - |
| Cash and cash equivalents at end of period | 3,669 | - | - |
Eledon Pharmaceuticals, Inc. (ELDN)
Eledon Pharmaceuticals, Inc. (ELDN)